000			02035 a2200589 4500
005			20250517140852.0
264		0	_c20171108
008			201711s 0 0 eng d
022			_a1872-8332
024	7		_a10.1016/j.lungcan.2016.12.019 _2doi
040			_aNLM _beng _cNLM
100	1		_aAwad, Mark M
245	0	0	_aAn open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). _h[electronic resource]
260			_bLung cancer (Amsterdam, Netherlands) _c02 2017
300			_a126-130 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
650	0	4	_aAdministration, Intravenous
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aCell Cycle Proteins _xadverse effects
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Recurrence, Local
650	0	4	_aNeoplasm Staging
650	0	4	_aProtein Serine-Threonine Kinases _xadverse effects
650	0	4	_aProto-Oncogene Proteins _xadverse effects
650	0	4	_aPteridines _xadministration & dosage
650	0	4	_aRecurrence
650	0	4	_aSmall Cell Lung Carcinoma _xdrug therapy
650	0	4	_aSmoking _xepidemiology
650	0	4	_aTreatment Failure
650	0	4	_aTreatment Outcome
650	0	4	_aPolo-Like Kinase 1
700	1		_aChu, Quincy S-C
700	1		_aGandhi, Leena
700	1		_aStephenson, Joe J
700	1		_aGovindan, Ramaswamy
700	1		_aBradford, Daniel S
700	1		_aBonomi, Philip D
700	1		_aEllison, David M
700	1		_aEaton, Keith D
700	1		_aFritsch, Holger
700	1		_aMunzert, Gerd
700	1		_aJohnson, Bruce E
700	1		_aSocinski, Mark A
773	0		_tLung cancer (Amsterdam, Netherlands) _gvol. 104 _gp. 126-130
856	4	0	_uhttps://doi.org/10.1016/j.lungcan.2016.12.019 _zAvailable from publisher's website
999			_c26891958 _d26891958